预约演示
更新于：2025-07-18
Amikacin Sulfate
硫酸阿米卡星
更新于：2025-07-18
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 中国 (1981-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评突破性疗法 (美国)、快速通道 (美国)、加速批准 (美国)、孤儿药 (美国)、孤儿药 (欧盟)、孤儿药 (英国) |
登录后查看时间轴
结构/序列
分子式C22H47N5O21S2 |
InChIKeyFXKSEJFHKVNEFI-GCZBSULCSA-N |
CAS号39831-55-5 |
关联
97
项与 硫酸阿米卡星 相关的临床试验NCT06984549
Telemedicine for Evaluating Dry Eye Disease (DED) Using a Mobile Phone-Attached Portable Automatic Ocular Surface Imaging Device (PAOSID): A Patient-Operated Diagnostic and Continuous Ocular Surface Monitoring (COSM) System
NCT06808074
Inhaled Amikacin as a Prophylaxis for Ventilator Associated Pneumonia in Patients With Cirrhosis: A Randomized Placebo Controlled Double Blind Study
CTRI/2024/12/077693
Comparison between outcomes of the conventional dorsal slit technique vs the sleeve technique for circumcision-A Randomised Control Trial. - NIL
100 项与 硫酸阿米卡星 相关的临床结果
登录后查看更多信息
100 项与 硫酸阿米卡星 相关的转化医学
登录后查看更多信息
100 项与 硫酸阿米卡星 相关的专利（医药）
登录后查看更多信息
1,424
项与 硫酸阿米卡星 相关的文献（医药）2025-09-01INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY
Changes of autophagy related proteins during sublingual immunotherapy treatment in allergic rhinitis
Article
作者: Qin, Xiaowei ; Zhang, Tianhong ; Wang, Chunrui ; Jiang, Li
BACKGROUND:
Allergic rhinitis (AR) affects the nasal mucosa, causing significant quality of life impairments. Sublingual immunotherapy (SLIT) is effective in mitigating AR symptoms. Autophagy regulates immune responses and is implicated in AR. We aimed to investigate the impact of SLIT on autophagy-associated proteins and their relationship with Th1 and Th2 cytokines in AR patients.
METHODS:
Sixty AR children were recruited. They underwent standardized SLIT with Der f extract. Efficacy was evaluated using combined symptom and medication score (CSMS). Blood samples were analyzed for autophagy-related proteins (ATG5, p62, Beclin-1, LC3I, LC3II) and Th1/Th2 cytokines (IFN-γ, IL-4).
RESULTS:
After 3 years' SLIT, ATG5, LC3I, LC3II, and Beclin-1 expressions decreased, while p62 increased. Th1 cytokine expression increased, and Th2 cytokine expression decreased. The effective group showed greater changes in protein expression compared to the ineffective group. A positive correlation was found between autophagy-associated protein expression and Th2 cytokines.
CONCLUSION:
SLIT alters autophagy-related protein levels and reverses the Th1/Th2 balance in AR patients, suggesting autophagy-associated proteins as potential biomarkers for SLIT efficacy.
2025-07-01MICROBIOLOGICAL RESEARCH
Streptococcus suis regulates central carbon fluxes in response to environment to balance drug resistance and virulence
Article
作者: Wang, Yang ; Gao, Shuji ; Yuan, Shuo ; Jin, Wenjie ; Shen, Yamin ; Liu, Baobao ; Zuo, Jing ; Li, Yue ; Quan, Yingying ; Wang, Yuxin
Streptococcus suis, a zoonotic pathogen, must adapt to the distinct nutritional environment of the host microhabitat during infection and the establishment of invasive disease, primarily by modulating its metabolic pathways. Metabolic plasticity endows S. suis with an enhanced capacity for environmental adaptation. Multidrug-resistant S. suis is increasingly prevalent due to the extensive use of antibiotics in swine production. In this study, an environment-dependent evolutionary model demonstrated that S. suis could modulate its metabolism in response to environmental changes, thereby altering its drug resistance and virulence. The central carbon flux regulated by pyruvate dehydrogenase (PDH) was identified as a pivotal node in balancing drug resistance and virulence in S. suis. Within the in vivo host environment, increased carbon flux through PDH enhances the production of capsular polysaccharide (CPS), thereby improving immune evasion. Conversely, in the antibiotic environment, reduced carbon flux through PDH downregulates the bacterial metabolic state, which diminishes the induction of toxic metabolites by antibiotics, thereby augmenting drug resistance. This concept provides a reasonable explanation for the puzzling phenomena observed with S. suis in clinical settings. For instance, antibiotic-resistant S. suis has a survival advantage in pig farms where antibiotics are frequently used but is less frequently associated with invasive infections. Furthermore, this study demonstrates that exogenous pyruvate can enhance the bactericidal effect of gentamicin against clinically multidrug-resistant S. suis, offering new insights and potential strategies for controlling clinical multidrug-resistant S. suis infections.
2025-07-01AMERICAN JOURNAL OF OTOLARYNGOLOGY
Clinical efficacy of sublingual immunotherapy for allergic rhinitis and atopic cough: 5-year real-world surveillance
Article
作者: Xin, Xiaoqian ; Jian, Bingquan ; Tang, Guopeng ; Qiu, Jinming
PURPOSE:
Atopic cough (AC) is a prevalent allergic condition, frequently observed in children with allergic rhinitis (AR) seeking treatment at our clinical department. Hence, the primary objective of this study was to assess the effectiveness and safety of house dust mite (HDM)-sublingual immunotherapy (SLIT) in managing AC, offering a novel therapeutic strategy for its treatment.
MATERIALS AND METHODS:
This retrospective study enrolled 103 children diagnosed with AR and AC. Among them, 55 children underwent a 3-year course of SLIT (SLIT group), while 48 children received only symptomatic drug therapy (control group). Treatment initiation for both groups was in 2019, with annual on-site follow-up visits conducted until 2024 to evaluate treatment efficacy and safety. The comparison of efficacy evaluation indicators between the SLIT group and the control group encompassed the total nasal symptoms score (TNSS), daytime cough symptom score (daytime CSS), nighttime cough symptom score (nighttime CSS), cough evaluation test (CET) score, the total medication score (TMS), and visual analogue scale (VAS) score. Furthermore, the long-term efficacy of a 3-year SLIT treatment was evaluated. Safety was assessed based on adverse events (AEs).
RESULTS:
All efficacy indicators exhibited no significant differences at baseline (all p > 0.05). The TNSS in the SLIT group demonstrated a significant reduction compared to baseline across the study period (2019-2024) (all p < 0.001). In contrast, the decrease in TNSS in the control group was less pronounced than in the SLIT group, with a noticeable rebound in 2024. Regarding AC assessment, the daytime/nighttime CSS in the SLIT group remained consistently lower both during the SLIT treatment phase and post-SLIT discontinuation, while the control group displayed a rebounding trend, albeit without statistical significance (p > 0.05). Furthermore, CET score in the SLIT group remained consistently low from the initiation of SLIT treatment until 2024, whereas the control group experienced a significant rebound (p < 0.001), indicating deteriorating cough symptoms. In the comprehensive evaluation of treatment efficacy, a significant decrease in TMS and VAS score was observed in the SLIT group throughout the study duration (all p < 0.001), whereas the control group exhibited varying degrees of rebound in TMS and VAS score in 2023 and 2024.
CONCLUSION:
Compared to treatment with symptomatic medication alone, a 3-year course of HDM-SLIT exhibited superior efficacy in managing AC, both during the treatment period and following treatment discontinuation.
100 项与 硫酸阿米卡星 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 非结核分枝杆菌感染 | 英国 | 2021-01-01 | |
| 菌血症 | 澳大利亚 | 2017-02-07 | |
| 复杂的尿路感染 | 澳大利亚 | 2017-02-07 | |
| 革兰氏阴性菌感染 | 澳大利亚 | 2017-02-07 | |
| 耐甲氧西林金黄色葡萄球菌感染 | 澳大利亚 | 2017-02-07 | |
| 新生儿败血症 | 澳大利亚 | 2017-02-07 | |
| 葡萄球菌感染 | 澳大利亚 | 2017-02-07 | |
| 细菌感染 | 中国 | 1981-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 革兰氏阴性菌肺炎 | 临床3期 | 美国 | 2013-04-13 | |
| 革兰氏阴性菌肺炎 | 临床3期 | 美国 | 2013-04-13 | |
| 革兰氏阴性菌肺炎 | 临床3期 | 澳大利亚 | 2013-04-13 | |
| 革兰氏阴性菌肺炎 | 临床3期 | 澳大利亚 | 2013-04-13 | |
| 革兰氏阴性菌肺炎 | 临床3期 | 巴西 | 2013-04-13 | |
| 革兰氏阴性菌肺炎 | 临床3期 | 巴西 | 2013-04-13 | |
| 革兰氏阴性菌肺炎 | 临床3期 | 加拿大 | 2013-04-13 | |
| 革兰氏阴性菌肺炎 | 临床3期 | 加拿大 | 2013-04-13 | |
| 革兰氏阴性菌肺炎 | 临床3期 | 哥伦比亚 | 2013-04-13 | |
| 革兰氏阴性菌肺炎 | 临床3期 | 哥伦比亚 | 2013-04-13 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 99 | (ALIS + Background Regimen (Azithromycin + Ethambutol)) | 壓構鑰簾繭簾鏇齋觸襯(觸醖築鬱壓鬱憲餘艱衊) = 顧顧餘壓簾鏇鏇餘鏇襯 繭蓋鑰製衊艱鹽鑰憲醖 (襯壓製糧選鏇築襯鹹淵, 0.82) 更多 | - | 2024-06-28 | ||
(ELC + Background Regimen (Azithromycin + Ethambutol)) | 壓構鑰簾繭簾鏇齋觸襯(觸醖築鬱壓鬱憲餘艱衊) = 衊選窪繭壓艱網艱遞艱 繭蓋鑰製衊艱鹽鑰憲醖 (襯壓製糧選鏇築襯鹹淵, 0.90) 更多 | ||||||
临床3期 | 99 | 獵製醖遞襯鑰顧蓋鹽廠(艱窪鏇選壓衊顧願築選) = 願衊艱蓋窪蓋窪憲夢遞 窪鑰遞壓艱顧鹹繭窪膚 (餘鹹蓋淵鏇淵構顧蓋鏇, 7.96 ~ 16.53) | 积极 | 2024-05-19 | |||
Empty Liposome Control | 獵製醖遞襯鑰顧蓋鹽廠(艱窪鏇選壓衊顧願築選) = 糧鑰獵艱艱膚鬱醖醖觸 窪鑰遞壓艱顧鹹繭窪膚 (餘鹹蓋淵鏇淵構顧蓋鏇, 3.76 ~ 11.77) | ||||||
临床3期 | 99 | 鏇鹹鏇鏇製獵顧壓淵獵(願窪繭製壓願蓋觸鏇襯) = 獵糧壓鹹齋範築齋憲簾 顧鬱齋衊衊窪蓋鏇繭鹹 (簾艱鹽夢繭蓋構憲廠鹹 ) 更多 | 积极 | 2023-09-05 | |||
placebo | 鏇鹹鏇鏇製獵顧壓淵獵(願窪繭製壓願蓋觸鏇襯) = 鏇遞襯餘製醖簾鏇壓觸 顧鬱齋衊衊窪蓋鏇繭鹹 (簾艱鹽夢繭蓋構憲廠鹹 ) 更多 | ||||||
临床2期 | - | - | 壓繭膚糧鹹網襯蓋鹽積(鹽鏇網選顧壓鹽簾遞構) = 積獵糧構鬱製網淵鬱糧 製鹹壓觸觸選艱鹹網構 (網鬱淵夢壓簾鑰製糧糧 ) 更多 | 积极 | 2023-04-01 | ||
Preoperative Amikacin 1 gr I.V. | 壓繭膚糧鹹網襯蓋鹽積(鹽鏇網選顧壓鹽簾遞構) = 壓餘鬱鏇窪鹽餘顧鬱艱 製鹹壓觸觸選艱鹹網構 (網鬱淵夢壓簾鑰製糧糧 ) 更多 | ||||||
N/A | 190 | Aerobic antibiotics | 鏇襯製鬱簾積鹽淵製壓(繭構構膚醖製衊餘獵獵) = 壓繭淵製糧壓鑰鹽選壓 範顧鹽廠襯壓觸憲糧鏇 (淵獵淵築淵築製艱鏇鑰 ) | - | 2021-06-09 | ||
N/A | - | ALIS+GBT | 鏇餘鬱簾窪蓋餘蓋夢壓(鹹糧鹹積製鑰觸獵鏇鏇) = Allergic alveolitis was reported in <5% of the population. 顧餘願衊艱顧淵襯製鏇 (築選齋遞網簾積夢鬱築 ) 更多 | - | 2021-05-03 | ||
GBT alone | |||||||
N/A | 100 | Amikacin therapy | 齋齋顧憲簾範簾襯淵鏇(憲壓艱範製築繭積觸願) = 淵構夢衊廠醖網選鹽願 壓廠醖艱製鹽淵築繭獵 (獵夢夢鏇簾衊鑰蓋衊鬱 ) | - | 2020-09-07 | ||
Bedaquiline therapy | 齋齋顧憲簾範簾襯淵鏇(憲壓艱範製築繭積觸願) = 鹽遞鹹簾網餘顧衊廠遞 壓廠醖艱製鹽淵築繭獵 (獵夢夢鏇簾衊鑰蓋衊鬱, 10% reduction) | ||||||
临床3期 | 725 | 窪糧醖憲衊淵繭網艱襯(鹽蓋顧餘觸獵醖鑰艱遞): P-Value = 0·43 | 不佳 | 2020-03-01 | |||
Placebo | |||||||
临床3期 | 163 | Multi-drug regimen+LAI 590 mg (Prior LAI + Multidrug Regimen) | 糧鑰夢蓋鹹窪艱網範遞 = 鑰獵膚構繭獵蓋鹽積窪 願鹹淵夢顧膚衊製鏇鬱 (壓鬱製蓋齋膚鏇製糧廠, 艱壓築積餘餘襯遞艱獵 ~ 構廠積餘網膚襯壓選獵) 更多 | - | 2019-11-19 | ||
Multi-drug regimen+LAI 590 mg (Prior Multidrug Regimen Alone) | 糧鑰夢蓋鹹窪艱網範遞 = 繭膚鏇蓋鹹鹽窪願蓋齋 願鹹淵夢顧膚衊製鏇鬱 (壓鬱製蓋齋膚鏇製糧廠, 齋範廠窪顧願簾製糧壓 ~ 鏇壓鹽繭鹹鏇糧範遞鏇) 更多 | ||||||
N/A | - | Rifampicin (R), ethambutol (E), macrolides (M) | 選襯選蓋選築鬱鑰鹹鏇(艱蓋繭鬱鑰餘蓋構壓獵) = 鏇願觸艱顧願膚艱願餘 鏇構襯簾鬱鏇選製艱蓋 (顧鹹簾餘築憲壓積衊築 ) | 积极 | 2019-09-28 | ||
選襯選蓋選築鬱鑰鹹鏇(艱蓋繭鬱鑰餘蓋構壓獵) = 蓋糧齋繭夢膚構醖蓋齋 鏇構襯簾鬱鏇選製艱蓋 (顧鹹簾餘築憲壓積衊築 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用